Contact this trialFirst, we need to learn more about you.
ALK Inhibitor
Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Dickson, Tennessee
This trial is testing whether a new drug, lorlatinib, is better than the standard drug, crizotinib, at treating patients with a certain type of lung cancer who have not yet received treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.